Lundbeck reported solid Q2 16 numbers, with both top line and bottom line coming in ahead of both consensus and our estimates. Revenue increased 3% yoy to DKK3.8bn (+5% at LC), driven by the continued outperformance of five key products (all at LC) – Abilify Maintena (+82%), Brintellix/Trintellix (+82%), Northera (+143%), Onfi (+46%) and Rexulti (sales of DKK193m), which more than offset the generic erosion of Xenazine (-38%) and the negative impact from the return of Azilect’s ri
30 Aug 2016
Excellent quarter; second successive guidance upgrade this year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Excellent quarter; second successive guidance upgrade this year
Lundbeck reported solid Q2 16 numbers, with both top line and bottom line coming in ahead of both consensus and our estimates. Revenue increased 3% yoy to DKK3.8bn (+5% at LC), driven by the continued outperformance of five key products (all at LC) – Abilify Maintena (+82%), Brintellix/Trintellix (+82%), Northera (+143%), Onfi (+46%) and Rexulti (sales of DKK193m), which more than offset the generic erosion of Xenazine (-38%) and the negative impact from the return of Azilect’s ri